Retatrutide cost per month is still unofficial: the drug isn't FDA-approved yet. See projected US prices, insurance realities, and grey-market risks.
There is no official retatrutide cost per month yet, because retatrutide is an investigational drug that the FDA has not approved for any use. If it launches for obesity, analysts expect a US list price somewhere around $900 to $1,300 per month, with a manufacturer self-pay program possibly landing near $300 to $500 per month. Until then, every "retatrutide price" you see online comes from a clinical trial, a projection, or an unregulated seller.
Why Nobody Can Quote a Real Retatrutide Price Today
Retatrutide is a triple agonist being developed by Eli Lilly. It targets the GIP, GLP-1, and glucagon receptors at the same time, which is one reason it gets so much attention in weight-loss research.
It is still in Phase 3 trials, which means a few practical things for pricing:
- No FDA approval means no published list price. Drug makers only announce a price after approval.
- No approval means no billing code and no insurance coverage. Insurers cannot cover a drug that does not legally exist on the market.
- No approval means no legal compounding. Retatrutide has never appeared on the FDA drug shortage list, so it is not eligible for large-scale compounding under federal rules.
Retatrutide is not FDA-approved for human use in the United States, and no pharmacy can legally fill a retatrutide prescription today. Searches for retatrutide precio or retatrutide precio en dólares run into the same wall: there is no official price to convert.
Retatrutide Cost Per Month: Realistic Projections
The table below shows how different sources could affect what you pay each month. These are estimates modeled on how existing GLP-1 obesity drugs are priced, not quotes from Eli Lilly.
| Source | Estimated monthly cost (USD) | Notes |
|---|---|---|
| Clinical trial | $0 | Trial sponsors cover the drug and monitoring |
| Insurance (if approved and covered) | $25–$150 copay | Likely prior authorization and step therapy |
| Manufacturer self-pay (projected) | $300–$500 | Modeled on Zepbound vials and NovoCare |
| Retail list price (projected) | $900–$1,300 | No official price has been announced |
| Grey-market "research" vials | $200–$800 | Unregulated, not for human use |
If you are asking how much does retatrutide cost right now, the honest answer is that no legitimate price exists. A projected list price is not a price you can pay today, and a grey-market listing is not a pharmacy.
Retatrutide Cost Per Month With Insurance vs Without Insurance
With insurance
Retatrutide insurance coverage does not exist yet, because coverage follows FDA approval. Once a drug is approved, insurers typically add prior authorization, documented BMI or diagnosis requirements, and step therapy that forces you to try cheaper drugs first.
Commercial plans often land at $25 to $150 per month for covered GLP-1 drugs. Medicare Part D coverage for obesity drugs remains limited, and many state Medicaid programs restrict them as well.
Without insurance
Self-pay pricing is where most real-world cost questions end up. Lilly's current obesity drug sells for roughly $349 to $499 per month through its direct-to-consumer pharmacy, and retatrutide would likely follow a similar playbook.
For context, the cost of ozempic per month sits near $900 at list price, with a self-pay option around $499. A retatrutide cost per month without insurance above $500 would likely push many patients toward older, cheaper alternatives.
How Retatrutide Compares to Tirzepatide and Cagrilintide
Cost only makes sense next to the alternatives a US patient can actually get. This comparison uses current market prices for approved drugs and projections for investigational ones.
| Drug | Status | Typical US monthly cost |
|---|---|---|
| Ozempic (semaglutide) | Approved for type 2 diabetes | ~$900 list; ~$499 self-pay |
| Wegovy (semaglutide) | Approved for obesity | ~$1,350 list; ~$499 self-pay |
| Zepbound (tirzepatide) | Approved for obesity | ~$1,060 list; $349–$499 vials |
| Cagrilintide | Investigational | No price; combination only |
| Retatrutide | Investigational | No price; projected $900–$1,300 |
When people look into cagrilintide vs retatrutide vs tirzepatide, only tirzepatide can be prescribed in the US today. That single fact drives most cost decisions, regardless of which molecule looks stronger in early trial data.
Retatrutide 10 mg Price and Grey-Market Realities
Grey-market sellers list retatrutide 10 mg vials anywhere from about $80 to $250, and a weekly 10 mg dose would mean four or more vials per month. That math produces a fake-looking "cheap retatrutide" price of $300 to $800 monthly with zero quality guarantee.
The same storefronts that advertise aod 9604 and retatrutide are usually the ones people check to see how much does aod 9604 cost, and the pattern is identical: no FDA oversight, no sterility testing, and no dosing guidance. Forum threads such as cjc-1295 ipamorelin dosage per day reddit show how quickly unverified advice spreads when no approved product exists.
- Vials may contain the wrong peptide, the wrong dose, or bacterial contamination.
- Cold-chain shipping is rarely verified, which can degrade the compound.
- There is no recourse if you are harmed.
Grey-market retatrutide is not a discount version of a real drug. It is an unapproved research chemical sold for laboratory use and relabeled for people.
What to Do While Retatrutide Is Still Unpriced
- Check clinical trial listings. Phase 3 programs such as TRIUMPH enroll participants at no cost, including monitoring.
- Talk to a healthcare professional about approved options. Tirzepatide and semaglutide have real prices, real safety data, and real prescriptions.
- Ask about manufacturer self-pay programs for currently approved drugs, which often undercut pharmacy list prices.
- Avoid grey-market purchases. The short-term savings come with unknown purity and unknown risk.
Retatrutide is not a cure for obesity, and no injectable weight-loss drug replaces diet, activity, or medical supervision. Reported side effects in trials include nausea, vomiting, diarrhea, and increased heart rate, which is why monitoring matters.
The bottom line: a real retatrutide cost per month will not exist until the FDA approves the drug. Any number you see before then is a projection or a warning sign.
Frequently Asked Questions
How much will retatrutide cost per month in the US?
No official price exists because retatrutide is not FDA-approved. Analysts project a list price of roughly $900 to $1,300 per month if it launches for obesity, with a manufacturer self-pay program possibly bringing it down to about $300 to $500 per month. These are estimates modeled on Zepbound and Wegovy, not confirmed figures.
Does insurance cover retatrutide?
No. Retatrutide insurance coverage cannot exist before FDA approval, because insurers only cover drugs with an approved indication and a billing code. If retatrutide is eventually approved, expect prior authorization, step therapy, and copays that typically range from $25 to $150 per month on commercial plans.
Is cheap retatrutide sold online safe?
No. Retatrutide has no approved version and cannot be legally compounded, so any vial sold online is an unregulated research chemical. These products are not tested for purity, sterility, or correct dosing, and there is no way to verify what is actually in the vial. Talk to a healthcare professional about approved alternatives instead.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.